Tobramycin Powder CAS 32986-56-4

Tobramycin can bind at the 30S and 50S binding sites, hindering the formation of the 70S complex and preventing mRNA from being translated into proteins, leading to cell death. It is mainly effective against gram-negative bacteria such as Pseudomonas aeruginosa, Escherichia coli, Klebsiella pneumoniae, Escherichia coli, Proteus mirabilis, and Citrobacter. Clinically, it is mainly used for severe infections caused by sensitive bacteria, such as burn infections, sepsis, respiratory system infections, urinary system infections, gallbladder and biliary tract infections, and severe soft tissue infections caused by gram-negative bacteria, especially Pseudomonas aeruginosa, Escherichia coli, and Klebsiella pneumoniae.

After intramuscular injection, absorption is rapid and complete. After local flushing or application, a certain amount can also be absorbed on the surface of the body. After absorption, it is mainly distributed in the extracellular fluid; Among them, 5-15% are redistributed to tissues and accumulate in renal cortical cells. The product can cross the placenta. The distribution volume is 0.26L/kg. The drug concentration in urine is high, and after intramuscular injection of 1mg/kg, the concentration in urine can reach 75-100 μ g/mL. After intramuscular injection of 1mg/kg, the blood drug concentration can reach 4 μ g/mL; The blood drug concentration of intravenous infusion of the above dose for 1 hour is similar to that of intramuscular injection. The protein binding rate is very low when t1/2 is between 1.9 and 2.2 hours. This product is not metabolized in the body and is excreted through glomerular filtration. Eliminate 85-93% of the administered dose within 24 hours. This product can be cleared through hemodialysis or peritoneal dialysis.

This product is suitable for neonatal sepsis, sepsis, central nervous system infections (including meningitis), urogenital system infections, lung infections, biliary tract infections, abdominal infections (and peritonitis), bone infections, skin and soft tissue infections (including burns), acute and chronic otitis media, sinusitis, etc. caused by Pseudomonas aeruginosa, Proteus (indole positive and negative), Escherichia coli, Klebsiella, Escherichia coli, Serratia, and Staphylococcus (including penicillin G and methicillin-resistant strains). This product can be administered by intrathecal injection simultaneously when used for Pseudomonas aeruginosa meningitis or ventricular inflammation; When used for bronchial and pulmonary infections, this product can be inhaled simultaneously as an adjuvant therapy. Tobramycin is ineffective against most Group D streptococcal infections. Used for bacterial infections of the eye such as conjunctivitis and keratitis, especially for Gram negative bacterial infections resistant to gentamicin, such as severe Pseudomonas aeruginosa infections.

1. The commonly used dosage for adults is intramuscular injection or intravenous drip, once at a dose of 1-1.7mg/kg based on body weight, every 8 hours, with a treatment course of 7-10 days. For critically ill infected patients, the dosage can be increased to 8mg/kg per day, administered intravenously in divided doses, but should be reduced as soon as the condition improves.
2. The commonly used dosage for children is intramuscular injection or intravenous drip, based on body weight, 2mg/kg for infants born 0-7 days ago, once every 12 hours; Infants and children 2mg/kg, once every 8 hours. Refer to Gentamicin Sulfate.
(1) The maintenance dose for patients with creatinine clearance rate below 70mL/min needs to be adjusted based on the measured creatinine clearance rate.
(2) Tobramycin powder must be fully diluted before intravenous infusion. Each dose can be added to 50-200mL of 5% glucose injection or sodium chloride injection to dilute into a solution with a concentration of 1mg/mL (0.1%), and the infusion should be completed within 30-60 minutes (infusion time should not be less than 20 minutes). The amount of diluted solution should be reduced accordingly when administering to children.
(3) This product is not suitable for subcutaneous injection as it can cause pain. It is generally believed that toxic reactions are prone to occur when the peak concentration of the drug exceeds 12 μ g/mL and the trough concentration exceeds 2 μ g/mL. One course of treatment should not exceed 7-10 days. Eye drops, 1-2 drops each time, every 2 hours. Apply to the eyes, apply an appropriate amount to the conjunctival sac twice a day, or apply once before bedtime.